The oral contraceptive market is focused on advanced innovative solutions
Global Oral Contraceptive Pills Market Report 2022 by The Business Research Company – Market Size, Trends and Global Forecast 2022-2026
LONDON, GREATER LONDON, UK, March 7, 2022 /EINPresswire.com/ — Major institutes and companies operating in the oral contraceptive sector are focused on developing innovative oral contraceptive solutions. For example, a group of scientists at the Massachusetts Institute of Technology (MIT) developed a birth control pill that should only be taken once a month. The star-shaped capsule can greatly minimize accidental pregnancies caused by users not taking their regular dose of the pill. The capsule is filled with gelatin, which, once swallowed, can remain in the abdomen for weeks, where hormones are slowly released to stop labor.
In January 2020, Theramex, a women’s specialty pharmaceutical company, announced the acquisition of rights to Zoely®, a patented oral contraceptive from Merck & Co for an undisclosed amount. This acquisition supports Theramex’s global expansion and expands its portfolio with innovative treatment options for women. Merck & Co. is a US-based multinational pharmaceutical company that has oral contraceptives in its product portfolio.
Read more about the Global Oral Contraceptives Market Report:
The global oral contraceptive market size is expected to grow from US$18.44 billion in 2021 to US$20.13 billion in 2022 at a compound annual growth rate (CAGR) of 9.2%. The growth of the market is largely driven by businesses resuming operations and adjusting to the new normal while recovering from the impact of COVID-19, which previously led to restrictive containment measures involving social distancing, teleworking and commercial closures activities had led to operational challenges. The global oral contraceptive market is expected to reach US$31.92 billion in 2026 at a CAGR of 12.2%.
Major players in the global oral contraceptive industry are Teva Pharmaceutical Industries Ltd, Bayer AG, Syzygy Healthcare, Mankind Pharma Ltd., Pfizer Inc., Piramal Enterprises Ltd., Ferring BV, Merck & Co. Inc., Johnson & Johnson and Lupine Pharmaceuticals inc
The high incidence of unwanted pregnancies is expected to drive the growth of the oral contraceptive market in the coming years. An unwanted pregnancy is a pregnancy that is always unwanted, such as a pregnancy where no children are planned. The University of California, San Francisco (UCSF) study shows that rates of unwanted pregnancy and abortion decreased significantly when women received a year-old oral contraceptive prescription. According to the World Health Organization (WHO), 74 million women living in lower-middle-income economies around the world register unwanted pregnancies every year. WHO research found that 4,794 women had an unplanned pregnancy after stopping contraceptive use.
According to the Oral Contraceptives market forecast, the need to avoid unwanted pregnancy is driving the growth of the Oral Contraceptives market.
TBRC Oral Contraceptive Pills market report is segmented by Type, Progestin Only, Others, by Category into Generic, Brands, by Distribution Channel into Hospital Pharmacy, Retail Pharmacy, Clinic, Online Channel, Public Channel, and NGO, Other.
Global Oral Contraceptive Pills Market Report 2022 – By Type (Combination, Progestin Only), By Category (Generic, Branded), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channel, Public Channel and NGO) – Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company providing Oral Contraceptives market overview, Oral Contraceptives market size forecast and Oral Contraceptives market growth for the market as a whole, Oral Contraceptives Market segments, Regions, Oral Contraceptives Market Trends, Oral Contraceptives Market Drivers, Restraints, Sales of Leading Competitors, Profiles and Market Shares.
Request Sample Global Oral Contraceptives Market Report :
Not what you were looking for? Here is a list of similar reports from The Business Research Company:
Hormonal Contraceptives Global Market Report 2021 – By Product (Oral Contraceptives, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Rings), By End-User (Hospitals, Home Care, Gynecology Centers, Clinics, Outpatient Surgical Centers), By Hormones (Progestin- Combined Hormones Only), By Distribution Channel (Drug stores, gynecology/fertility clinics, e-commerce), impact and recovery from COVID-19
Gynecology Drugs Global Market Report 2022 – By Therapeutics (Hormone Therapy, Non-Hormonal Therapy), By Indication (Gynecologic Cancers, Menopausal Disorder, Polycystic Ovary Syndrome, Contraception), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends and global forecast 2022-2026
Global Polycystic Ovary Syndrome Treatment Market Report 2022 – By Drug Type (Oral Contraceptives, Ornithine Decarboxylase Inhibitors, Insulin Sensitizing Agents, Antidepressants, Diuretics, Aromatase Inhibitors), By Surgery Type (Ovarian Wedge Resection, Laparoscopic Ovarian Drilling), By End Users (Hospitals and Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Gynecology Centers, Feminist Health Centers) – Market Size, Trends and Global Forecast 2022-2026
Learn more about the economic research company?
The Business Research Company is a market research and information firm that excels in business, market and consumer research. It has over 200 research professionals in its offices in India, the UK and the US, and a network of trained researchers worldwide. It has specialized consultants in a variety of industries including manufacturing, healthcare, financial services and technology.
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx
Call us now for personal advice on your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Check out our:
Market Research Products, Services, Solutions for your Business – TBRC